ClinicalTrials.gg
CompletedNCT02489344Updated Mar 23, 2021Results posted

Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease

A Phase 2 interventional study of GZ/SAR402671 in Fabry Disease, sponsored by Genzyme, a Sanofi Company. Completed at 7 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-23.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Fabry Disease by Sanofi — 1 open to participants now, 3 under way, 2 of them phase 3. Fabry Disease · Sanofi.

Enrollment
14th of 19
8 · median 20
Started
2015
the only one that year
Phase 2
5 of 23
none open now
Registered
16th of 23
by date

Among the 23 studies in Fabry Disease by Sanofi, this one is the 14th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2015, is one of 5 in phase 2, and was the 16th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

1 of the 23 studies in Fabry Disease by Sanofi is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Fabry Disease by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To assess the long-term safety of GZ/SAR402671 in adult male participants with Fabry disease who previously completed study ACT13739 (NCT02489344).

Secondary Objective:

To assess the long-term effect of GZ/SAR402671 on pharmacodynamic and exploratory efficacy endpoints in adult male participants with Fabry disease who previously completed study ACT13739.

Read the detailed description

The total duration of this extension study (LTS14116) was up to 31 months (30 months of treatment and one month post-treatment follow-up).

03

Conditions studied

  • Fabry Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participant with Fabry disease who previously completed study ACT13739.
  • Participants, willing and able to provide signed .
  • Sexually active participants, willing to practice true abstinence in line with their preferred and usual lifestyle or using two acceptable effective methods of .

Exclusion criteria

Exclusion criteria :

-Participants, in the opinion of the Investigator, unable to adhere to the requirements of the study.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    GZ/SAR402671

    Participants received GZ/SAR402671 15 milligrams (mg) once daily orally for 30 months in this extension study (LTS14116).

    Drug: GZ/SAR402671

Interventions

  • DrugGZ/SAR402671

    Drug page: Venglustat

    Pharmaceutical form:capsule Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened during TEAE period (period from the first administration of study drug in ACT13739 through the last administration of the study drug in the combined ACT13739/LTS14116 treatment period plus 1 month or end of study participation for participant, whichever occurred first). For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline

  2. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters

    Criteria for potentially clinically significant abnormalities: * Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L); greater than or equal to (\>=)185 g/L; decreased from baseline (DFB) \>=20 g/L * Hematocrit: \<=0.37 volume/volume (v/v); \>=0.55 v/v * Erythrocytes: \>=6 Tera/L * Platelets: lesser than (\<) 100 Giga/L; \>=700 Giga/L * Leukocytes: \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); * Lymphocytes: greater than (\>) 4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L) For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline

  3. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes

    Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 millimoles (mmol)/L; \>=160 mmol/L * Potassium: \<3 mmol/L; \>=5.5 mmol/L * Chloride: \<80 mmol/L; \>115 mmol/L.

    Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline

  4. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters

    Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>3 ULN; \>5 ULN; \>10 ULN and \>20 ULN * Aspartate aminotransferase (AST): \>3 ULN; \>5 ULN; \>10 ULN and \>20 ULN * Alkaline phosphatase: \>1.5 ULN * Bilirubin: \>1.5 ULN; \>2 ULN.

    Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline

  5. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters

    Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \< lower limits of normal (LLN); \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]) * Lipase: \>= 3 ULN * C Reactive Protein (CRP): \> 2 ULN or \> 10 milligrams (mg)/L (if ULN not provided).

    Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline

  6. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters

    Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromoles per liter (mcmol/L) (Adults); \>=30% change from baseline; \>= 100% change from baseline * Blood urea nitrogen: \>=17 mmol/L * Urate: \<120 mcmol/L; \>408 mcmol/L For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline

  7. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Urinalysis

    Criteria with potentially clinically significant urine abnormalities: pH: \<= 4.6; pH: \>= 8.0

    Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline

  8. Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities

    Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure (SBP) supine: \<=95 millimeters of mercury (mmHg) and DFB \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg * Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg * Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm * Weight: \>=5% DFB; \>=5% IFB For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline

  9. Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

    Criteria for potentially clinically significant ECG abnormalities: * ECG mean HR: \<30 bpm; \<30 bpm and DFB \>=20 bpm; \<40 bpm; \<40 bpm and DFB \>=20 bpm; \<50 bpm; \<50 bpm and DFB \>=20 bpm; \>90 bpm; \<90 bpm and DFB \>=20 bpm; \>100 bpm; \<100 bpm and DFB \>=20 bpm; \>120 bpm; \<120 bpm and DFB \>=20 bpm * PR Interval: \>200 milliseconds (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25% * QRS duration: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25% * QTc Bazett (QTcB) interval: \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms, IFB \>60 ms * QTc Fridericia (QTc F): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms * QT Interval: \>500 ms For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: From baseline of ACT13739 study up to 37 months post-ACT13739 baseline

Secondary outcomes

  1. Change From Baseline in Plasma Globotriaosylceramide (GL-3) Concentration at Weeks 26, 52, 104, and 156

    Change from baseline in plasma GL-3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GL-3 in plasma was determined using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline

  2. Change From Baseline in Plasma Lyso Globotriaosylceramide (Lyso GL-3) Concentration at Weeks 26, 52, 104, and 156

    Change from baseline in plasma GL-3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of lyso-GL-3 in plasma was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline

  3. Change From Baseline in Plasma Glucosylceramide (GL-1) Concentration At Weeks 26, 52, 104, and 156

    Change from baseline in plasma GL-1 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GL-1 in plasma was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline

  4. Change From Baseline in Plasma Monosialodihexosylganglioside (GM3) Concentration At Weeks 26, 52, 104, and 156

    Change from baseline in plasma GM3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GM3 in plasma was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline

  5. Change From Baseline in Urine GL-3 Concentration At Weeks 26, 52, 104, and 156

    Change from baseline in urine GL-3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GL-3 in urine was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline

  6. Change From Baseline in High Sensitivity Cardiac Troponin T At Weeks 26, 52, 104, and 156

    Change from baseline in high sensitivity cardiac troponin T was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline

  7. Change From Baseline in Podocyturia Counts (Per Milligram of Creatinine) At Weeks 12, 26, and 156

    Change from baseline in podocyturia was obtained by subtracting baseline value from post-baseline value at Weeks 12, 26, and 156. Urine samples were processed to identify podocyte (podocalyxin, PCX) and parietal cell (claudin 1, CL1) markers. PCX +/CL1 negative cells were identified as podocytes and PCX +/CL1 positive cells as parietal cells with podocyte phenotype. All counts were corrected for urine Cr. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 12, 26, and 156 post-ACT13739 baseline

  8. Summary of Shifts From Baseline in Skin GL-3 Score in Superficial Capillary Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score

    Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 12, 26, 52, and 156 post-ACT13739 baseline

  9. Summary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score

    Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 12, 26, 52, and 156 post-ACT13739 baseline

  10. Summary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score

    Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 12, 26, 52, and 156 post-ACT13739 baseline

  11. Summary of Shifts From Baseline in Skin GL-3 Score in Perineurium Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score

    Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 12, 26, 52, and 156 post-ACT13739 baseline

  12. Change From Baseline in Mental Component Summary and Physical Component Summary of the Short Form-36 (SF-36) Health Survey at Weeks 26, 52, 104 and 156

    The SF-36 health survey is a participant-reported survey to measure participant's health. It is a 36-item questionnaire used to measure 8 various aspects of health (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health). The score range for each of the 8 aspects was from 0 (maximum disability) to 100 (no disability), higher scores indicating good health condition. Responses on the SF-36 were also used to calculate 2 summary scores: Physical component score (PCS) and mental component score (MCS). The score range for each of these 2 summary scores was from 0 (maximum disability) to 100 (no disability), where higher score indicated less disability or good health condition. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline

  13. Gastrointestinal (GI) Symptoms: Number of Participants With Abdominal Pain at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

    Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the presence of abdominal pain in past 10 days (before each of the specified time points). Participants answered the question: "Do you currently suffer from abdominal (tummy) pain? \[Yes/No\]". For this analysis, baseline was defined as initial ACT13739 study.

    Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline

  14. Gastrointestinal Symptoms: Abdominal Pain Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

    Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark the severity of the abdominal pain in past 10 days (before each of the specified time points) on a visual analogue scale (VAS). The scale ranged from 0% (no pain) to 100% (very severe), where higher score indicated more severity. For this analysis, baseline was defined as initial ACT13739 study baseline. Standard deviation (SD) can only be calculated when there are more than 1 participant with data available. Thereby, applicable fields were left blank when SD was not calculable.

    Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline

  15. Gastrointestinal Symptoms: Number of Days With Abdominal Pain Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

    Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the number of days they had abdominal pain in past 10 days (before each of the specified time points). Number of days with abdominal pain score was achieved by multiplying number of days with pain \* 10. The score ranges from 10 to 100, where higher score signifies more number of days with pain. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline

  16. Gastrointestinal Symptoms: Number of Participants With Abdominal Distension at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

    Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the presence of abdominal distention in past 10 days (before each of the specified time points). Participants answered the question: "Do you currently suffer from abdominal distension (bloating, swelling or tight tummy)? \[Yes/No\]". For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline

  17. Gastrointestinal Symptoms: Abdominal Distension Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, and 156

    Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark the severity of the abdominal distension in past 10 days (before each of the specified time points) on a VAS. The scale ranged from 0% (no distention) to 100% (very severe), where higher score indicated more severity. For this analysis, baseline was defined as initial ACT13739 study baseline. The SD can only be calculated when there are more than 1 participant with data available. Thereby, applicable fields were left blank when SD was not calculable.

    Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, and 156 post-ACT13739 baseline

  18. Gastrointestinal Symptoms: Number of Participants in Categories of Response Regarding Eating Less Due to Abdominal Pain/Bloating at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

    Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants responded to question "How often do you eat less during meals due to abdominal pain and/or bloating?" in past 10 days (before each of the specified time points) in the categories as 'never', 'occasionally' or 'often'. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline

  19. Gastrointestinal Symptoms: Satisfaction Over Bowel Habits at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

    Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark their satisfaction over bowel habits in past 10 days (before each of the specified time points) on a VAS. The scale ranged from 0% (very happy) to 100% (very unhappy), where higher percentage indicated less satisfaction. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline

  20. Gastrointestinal Symptoms: Frequency of Bowel Movements - Most Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

    Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the frequency of their bowel movement (per day or per week or per month) in past 10 days (before each of the specified time points) by answering the question "What is the most number of times you move your bowels per day/week/month?". Participants selected their preferred time unit (e.g., per day). Response provided by participants was converted to number of times per day for reporting the results. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline

  21. Gastrointestinal Symptoms: Frequency of Bowel Movements - Least Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

    Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the frequency of their bowel movement (per day or per week or per month) in past 10 days (before each of the specified time points). Participants answered the question "What is the least number of times you move your bowels per day/week/month?". Participants selected their preferred time unit (e.g., per day). Response provided by participants was converted to number of times per day for reporting the results. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline

  22. Gastrointestinal Symptoms: Influence of GI Symptoms of Fabry Disease on Life at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

    Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark the influence of their GI symptoms of Fabry disease on life in past 10 days (before each of the specified time points) on a VAS. The scale ranged from 0% (no at all) to 100% (completely), where higher percentage indicated more influence of the GI symptoms of the disease on life. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline

  23. Gastrointestinal Symptoms: Number of Participants With Stool Consistency Assessment by Bristol Stool Scale Scoring at Baseline and Weeks 26, 52, 104, and 156

    Participants were asked to rate their stool consistency in past 10 days (before each of the specified time points) on a 7-point Bristol stool scale, according to the following types: 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces. Types 1 and 2 indicate constipation, types 3 and 4 indicate "ideal stools" (easiest to defecate), and 5-7 tending towards diarrhea. Frequency of each stool type was categorized as 'never', occasionally', or 'often'. For this analysis, baseline was defined as the initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline

  24. Change From Baseline in Beck Depression Inventory (BDI) Total Score at Weeks 26, 104, and 156

    The BDI-II Scale was a 21-item scoring tool which measures the existence and severity of symptoms of depression. Each of the 21 items on BDI-II tool represent a depressive symptom. Each symptoms were scored on a 4-point scale of 0 to 3 (0=symptom not present); (3=symptom very intense). Scores for each symptom were added up to obtain the total scores for all 21 items, which were interpreted as follows: Scores of 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression and 29-63: severe depression, where higher scores indicated more depression. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 26, 104, and 156 post-ACT13739 baseline

  25. Change From Baseline in Albumin/Creatinine Ratio (ACR) and Protein/Creatinine Ratio (PCR) at Weeks 26, 52, 104, and 156

    For each scheduled visit for this assessment, 3 timed overnight urine samples were collected between 4 to 7 days of each other. All urine samples were collected within a 16-day period. ACR and PCR were determined for each collection. The median of the values determined for the 3 collections/visit was used for analysis. Baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline

  26. Number of Participants in Categories of Echocardiogram (ECHO) Results at Baseline and at Weeks 26, 52, 104, and 156

    The summary statistics of all continuous echocardiogram variables were calculated for each visit. The overall interpretation of the readings were summarized in 3 categories: normal, abnormal but not clinically significant (NCS), and abnormal but clinically significant (CS) categories. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline

  27. Number of Participants in Categories of Brain Magnetic Resonance Imaging (MRI) Results at Baseline and Weeks 26, and 156

    All continuous MRI variables were summarized using descriptive statistics for each visit. The overall interpretation of the readings were summarized in 2 categories as: normal, and abnormal. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 26, and 156 post-ACT13739 baseline

  28. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Weeks 26, 52, 104, and 156

    Estimated glomerular filtration rate was used to measure level of kidney function and determine the stage of kidney disease. Change from baseline in eGFR was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104 and 156. For this analysis, baseline was defined as initial ACT13739 study baseline.

    Time frame: Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline

  29. Chitotriosidase (Chit1) Plasma Concentration Levels at Weeks 52, 104,156 and 160 (End of Treatment Follow-up)

    Plasma concentrations of Chit1 over time were determined using mass spectrometry (MS)-based assay. For the analysis, 52 ng/mL was considered as the lower limit of quantification. Although identified in protocol as a secondary endpoint, plasma Chit1 is also an exploratory measure. Only LTS14116 timepoints were analyzed and are presented. Data summarized are the measured values at each time point (not change from baseline). Here, measured value '0.000' denotes no chitotriosidase detected in plasma for the 5 participants at Week 156 reported by laboratory for all evaluable participants.

    Time frame: Weeks 52, 104, 156 and 160 (End of Treatment Follow-up) post-ACT13739 baseline

07

Results

Posted Dec 9, 2019

Participant flow

Participants who successfully completed 26 weeks of treatment in prior ACT13739 study (NCT02228460) were eligible to continue their treatment for up to 30 additional months in this extension study LTS14116. Eleven participants had enrolled and were treated in ACT13739 study, and 9 completed study. Of these 9 participants, 8 entered extension study.

ACT13739 (Initial Study): 26 Weeks
Participant flow — ACT13739 (Initial Study): 26 Weeks
MilestoneGZ/SAR402671
Started11
Completed9
Not completed2
Withdrew: Adverse event1
Withdrew: Lost to follow-up1
LTS14116 (Extension Study): 31 Months
Participant flow — LTS14116 (Extension Study): 31 Months
MilestoneGZ/SAR402671
Started8
Completed5
Not completed3
Withdrew: Adverse event1
Withdrew: Treatment completed/study not completed2

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened during TEAE period (period from the first administration of study drug in ACT13739 through the last administration of the study drug in the combined ACT13739/LTS14116 treatment period plus 1 month or end of study participation for participant, whichever occurred first). For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsGZ/SAR402671
Number of Participants With Treatment Emergent Adverse Events (TEAEs)9
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters

Criteria for potentially clinically significant abnormalities: * Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L); greater than or equal to (\>=)185 g/L; decreased from baseline (DFB) \>=20 g/L * Hematocrit: \<=0.37 volume/volume (v/v); \>=0.55 v/v * Erythrocytes: \>=6 Tera/L * Platelets: lesser than (\<) 100 Giga/L; \>=700 Giga/L * Leukocytes: \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); * Lymphocytes: greater than (\>) 4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L) For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters
ParticipantsGZ/SAR402671
Hemoglobin <=115 g/L1
Hemoglobin >=185 g/L0
Hemoglobin DFB >=20 g/L0
Hematocrit <=0.37 v/v6
Hematocrit >0.55 v/v0
Erythrocytes: >=6 Tera/L0
Platelets <100 Giga/L0
Platelets >=700 Giga/L0
Leukocytes <3.0 Giga/L (NB) or <2.0 Giga/L (B)0
Leukocytes >=16.0 Giga/L0
Neutrophils <1.5 Giga/L (NB) or <1.0 Giga/L (B)0
Lymphocytes >4.0 Giga/L0
Monocytes >0.7 Giga/L2
Basophils >0.1 Giga/L1
Eosinophils >0.5 Giga/L or >ULN (ULN >=0.5 Giga/L)0
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes

Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 millimoles (mmol)/L; \>=160 mmol/L * Potassium: \<3 mmol/L; \>=5.5 mmol/L * Chloride: \<80 mmol/L; \>115 mmol/L.

Time frame:
From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes
ParticipantsGZ/SAR402671
Sodium <=129 mmol/L0
Sodium >=160 mmol/L0
Potassium <3 mmol/L0
Potassium >=5.5 mmol/L0
Chloride <80 mmol/L0
Chloride >115 mmol/L0
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters

Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>3 ULN; \>5 ULN; \>10 ULN and \>20 ULN * Aspartate aminotransferase (AST): \>3 ULN; \>5 ULN; \>10 ULN and \>20 ULN * Alkaline phosphatase: \>1.5 ULN * Bilirubin: \>1.5 ULN; \>2 ULN.

Time frame:
From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters
ParticipantsGZ/SAR402671
ALT >3 ULN0
ALT >5 ULN0
ALT >10 ULN0
ALT >20 ULN0
AST >3 ULN0
AST >5 ULN0
AST >10 ULN0
AST >20 ULN0
Alkaline Phosphatase >1.5 ULN0
Bilirubin >1.5 ULN0
Bilirubin >2 ULN0
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters

Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \< lower limits of normal (LLN); \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]) * Lipase: \>= 3 ULN * C Reactive Protein (CRP): \> 2 ULN or \> 10 milligrams (mg)/L (if ULN not provided).

Time frame:
From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters
ParticipantsGZ/SAR402671
Glucose <=3.9 mmol/L and <LLN3
Glucose >=11.1 mmol/L (unfas) or >=7 mmol/L (fas)1
Albumin <=25 g/L0
Lipase >=3 ULN0
CRP >2 ULN or >10 mg/L (if ULN not provided)2
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters

Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromoles per liter (mcmol/L) (Adults); \>=30% change from baseline; \>= 100% change from baseline * Blood urea nitrogen: \>=17 mmol/L * Urate: \<120 mcmol/L; \>408 mcmol/L For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters
ParticipantsGZ/SAR402671
Creatinine >=150 mcmol/L0
Creatinine >=30% change from baseline2
Creatinine >=100% change from baseline0
Blood Urea Nitrogen >=17 mmol/L0
Urate <120 mcmol/L0
Urate >408 mcmol/L5
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Urinalysis

Criteria with potentially clinically significant urine abnormalities: pH: \<= 4.6; pH: \>= 8.0

Time frame:
From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Urinalysis
ParticipantsGZ/SAR402671
pH <= 4.60
pH >= 8.00
PrimaryNumber of Participants With Potentially Clinically Significant Vital Signs Abnormalities

Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure (SBP) supine: \<=95 millimeters of mercury (mmHg) and DFB \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg * Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg * Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm * Weight: \>=5% DFB; \>=5% IFB For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
ParticipantsGZ/SAR402671
SBP (supine) <=95 mmHg and DFB >=20 mmHg0
SBP (supine) >=160 mmHg and IFB >=20 mmHg0
DBP (supine) <=45 mmHg and DFB >=10 mmHg0
DBP (supine) >=110 mmHg and IFB >=10 mmHg0
HR (supine) <=50 bpm and DFB >= 20 bpm1
HR (supine) >=120 bpm and IFB >=20 bpm0
Weight >=5% DFB3
Weight >=5% IFB2
PrimaryNumber of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

Criteria for potentially clinically significant ECG abnormalities: * ECG mean HR: \<30 bpm; \<30 bpm and DFB \>=20 bpm; \<40 bpm; \<40 bpm and DFB \>=20 bpm; \<50 bpm; \<50 bpm and DFB \>=20 bpm; \>90 bpm; \<90 bpm and DFB \>=20 bpm; \>100 bpm; \<100 bpm and DFB \>=20 bpm; \>120 bpm; \<120 bpm and DFB \>=20 bpm * PR Interval: \>200 milliseconds (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25% * QRS duration: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25% * QTc Bazett (QTcB) interval: \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms, IFB \>60 ms * QTc Fridericia (QTc F): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms * QT Interval: \>500 ms For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
From baseline of ACT13739 study up to 37 months post-ACT13739 baseline
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
ParticipantsGZ/SAR402671
ECG Mean HR <30 bpm0
ECG Mean HR <30 bpm and DFB >=20 bpm0
ECG Mean HR <40 bpm0
ECG Mean HR <40 bpm and DFB >=20 bpm0
ECG Mean HR <50 bpm1
ECG Mean HR <50 bpm and DFB >=20 bpm0
ECG Mean HR >90 bpm1
ECG Mean HR <90 bpm and DFB >=20 bpm0
ECG Mean HR >100 bpm0
ECG Mean HR <100 bpm and DFB >=20 bpm0
ECG Mean HR >120 bpm0
ECG Mean HR <120 bpm and DFB >=20 bpm0
PR interval >200 ms2
PR interval >200 ms and IFB >=25%0
PR interval >220 ms0
PR interval >220 ms and IFB >=25%0
PR >240 ms0
PR interval >240 ms and IFB >=25%0
QRS duration >110 ms1
QRS duration >110 ms and IFB >=25%0
QRS duration >120 ms0
QRS duration >120 ms and IFB >=25%0
QTcB interval >450 ms0
QTcB interval >480 ms0
QTc B interval >500 ms0
QTcB interval IFB >30 and <=60 ms1
QTcB interval IFB >60 ms0
QTcF interval >450 ms0
QTc F interval >480 ms0
QTcF interval >500 ms0
QTcF interval IFB >30 and <=60 ms0
QTcF interval IFB >60 ms0
QT interval >500 ms0
SecondaryChange From Baseline in Plasma Globotriaosylceramide (GL-3) Concentration at Weeks 26, 52, 104, and 156

Change from baseline in plasma GL-3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GL-3 in plasma was determined using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Change From Baseline in Plasma Globotriaosylceramide (GL-3) Concentration at Weeks 26, 52, 104, and 156
micrograms per milliliter (mcg/mL)GZ/SAR402671
Week 26-3.62 ± 1.07
Week 52-5.06 ± 1.04
Week 104-6.32 ± 2.53
Week 156-6.97 ± 2.27
SecondaryChange From Baseline in Plasma Lyso Globotriaosylceramide (Lyso GL-3) Concentration at Weeks 26, 52, 104, and 156

Change from baseline in plasma GL-3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of lyso-GL-3 in plasma was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · nanograms per mL (ng/mL)
Change From Baseline in Plasma Lyso Globotriaosylceramide (Lyso GL-3) Concentration at Weeks 26, 52, 104, and 156
nanograms per mL (ng/mL)GZ/SAR402671
Week 26-30.99 ± 22.83
Week 52-37.10 ± 20.69
Week 104-39.84 ± 18.12
Week 156-48.13 ± 15.65
SecondaryChange From Baseline in Plasma Glucosylceramide (GL-1) Concentration At Weeks 26, 52, 104, and 156

Change from baseline in plasma GL-1 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GL-1 in plasma was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · mcg/mL
Change From Baseline in Plasma Glucosylceramide (GL-1) Concentration At Weeks 26, 52, 104, and 156
mcg/mLGZ/SAR402671
Week 26-3.26 ± 1.43
Week 52-3.58 ± 0.85
Week 104-3.70 ± 0.85
Week 156-3.23 ± 1.11
SecondaryChange From Baseline in Plasma Monosialodihexosylganglioside (GM3) Concentration At Weeks 26, 52, 104, and 156

Change from baseline in plasma GM3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GM3 in plasma was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · mcg/mL
Change From Baseline in Plasma Monosialodihexosylganglioside (GM3) Concentration At Weeks 26, 52, 104, and 156
mcg/mLGZ/SAR402671
Week 26-10.77 ± 6.02
Week 52-8.84 ± 4.55
Week 104-9.92 ± 3.26
Week 156-8.12 ± 5.37
SecondaryChange From Baseline in Urine GL-3 Concentration At Weeks 26, 52, 104, and 156

Change from baseline in urine GL-3 was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. Concentration of GL-3 in urine was determined using a validated LC-MS/MS method. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · mg/mmol creatinine (Cr)
Change From Baseline in Urine GL-3 Concentration At Weeks 26, 52, 104, and 156
mg/mmol creatinine (Cr)GZ/SAR402671
Week 26-0.25 ± 0.19
Week 52-0.20 ± 0.22
Week 104-0.18 ± 0.22
Week 156-0.18 ± 0.27
SecondaryChange From Baseline in High Sensitivity Cardiac Troponin T At Weeks 26, 52, 104, and 156

Change from baseline in high sensitivity cardiac troponin T was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104, and 156. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · mcg/L
Change From Baseline in High Sensitivity Cardiac Troponin T At Weeks 26, 52, 104, and 156
mcg/LGZ/SAR402671
Week 260.0000 ± 0.0000
Week 520.0105 ± 0.0241
Week 104-0.0015 ± 0.0000
Week 1560.0006 ± 0.0027
SecondaryChange From Baseline in Podocyturia Counts (Per Milligram of Creatinine) At Weeks 12, 26, and 156

Change from baseline in podocyturia was obtained by subtracting baseline value from post-baseline value at Weeks 12, 26, and 156. Urine samples were processed to identify podocyte (podocalyxin, PCX) and parietal cell (claudin 1, CL1) markers. PCX +/CL1 negative cells were identified as podocytes and PCX +/CL1 positive cells as parietal cells with podocyte phenotype. All counts were corrected for urine Cr. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 12, 26, and 156 post-ACT13739 baseline
Reported as:
Mean · Count of podocytes/mg Cr
Change From Baseline in Podocyturia Counts (Per Milligram of Creatinine) At Weeks 12, 26, and 156
Count of podocytes/mg CrGZ/SAR402671
Week 12-1.40 ± 2.69
Week 26-1.65 ± 2.97
Week 156-2.73 ± 3.97
SecondarySummary of Shifts From Baseline in Skin GL-3 Score in Superficial Capillary Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score

Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 12, 26, 52, and 156 post-ACT13739 baseline
Reported as:
Count of participants · Participants
Summary of Shifts From Baseline in Skin GL-3 Score in Superficial Capillary Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score
ParticipantsGZ/SAR402671
Baseline Score:1/Week 12 Score:14
Baseline Score:1/Week 12 Score:21
Baseline Score:2/Week 12 Score:13
Baseline Score:2/Week 12 Score:21
Baseline Score:1/Week 26 Score:14
Baseline Score:1/Week 26 Score:21
Baseline Score:2/Week 26 Score:13
Baseline Score:2/Week 26 Score:21
Baseline Score:1/Week 52 Score:13
Baseline Score:2/Week 52 Score:12
Baseline Score:2/Week 52 Score:21
Baseline Score:1/Week 156 Score:02
Baseline Sore:1/Week 156 Score:11
Baseline Score:2/Week 156 Score:13
SecondarySummary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score

Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 12, 26, 52, and 156 post-ACT13739 baseline
Reported as:
Count of participants · Participants
Summary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score
ParticipantsGZ/SAR402671
Baseline Score:1/Week 12 Score:21
Baseline Score:2/Week 12 Score:12
Baseline Score:2/Week 12 Score:26
Baseline Score:1/Week 26 Score:11
Baseline Score:2/Week 26 Score:12
Baseline Score:2/Week 26 Score:26
Baseline Score:2/Week 52 Score:13
Baseline Score:2/Week 52 Score:1.51
Baseline Sore:2/Week 52 Score:22
Baseline Score:1/Week 156 Score:11
Baseline Score:2/Week 156 Score:0.51
Baseline Score:2/Week 156 Score:13
Baseline Score:2/Week 156 Score:21
SecondarySummary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score

Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 12, 26, 52, and 156 post-ACT13739 baseline
Reported as:
Count of participants · Participants
Summary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score
ParticipantsGZ/SAR402671
Baseline Score:1.5/Week 12 Score:22
Baseline Score:2/Week 12 Score:27
Baseline Score:1.5/Week 26 Score:1.52
Baseline Score:2/Week 26 Score:27
Baseline Score:1.5/Week 52 Score:21
Baseline Score:2/Week 52 Score:24
Baseline Score:1.5/Week 156 Score:21
Baseline Score:2/Week 156 Score:11
Baseline Score:2/Week 156 Score:1.51
Baseline Score:2/Week 156 Score:23
SecondarySummary of Shifts From Baseline in Skin GL-3 Score in Perineurium Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score

Skin biopsies were performed for the scoring of GL-3 accumulation/inclusions by light microscopy. Three independent pathologists scored GL-3 clearance by using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from baseline GL-3 score to Weeks 12, 26, 52, and 156 GL-3 score. Shift to lower score from baseline indicated less severe condition at that respective time point. Any shift category of Baseline score/Week score that was not observed (no participant had data in the category) was not reported. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 12, 26, 52, and 156 post-ACT13739 baseline
Reported as:
Count of participants · Participants
Summary of Shifts From Baseline in Skin GL-3 Score in Perineurium Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score
ParticipantsGZ/SAR402671
Baseline Score:1/Week 12 Score:21
Baseline Score:2/Week 12 Score:28
Baseline Score:1/Week 26 Score:21
Baseline Score:2/Week 26 Score:28
Baseline Score:1/Week 52 Score:21
Baseline Score:2/Week 52 Score:11
Baseline Score:2/Week 52 Score:1.51
Baseline Score:2/Week 52 Score:23
Baseline Score:1/Week 156 Score:11
Baseline Score:2/Week 156 Score:1.51
Baseline Score:2/Week 156 Score:24
SecondaryChange From Baseline in Mental Component Summary and Physical Component Summary of the Short Form-36 (SF-36) Health Survey at Weeks 26, 52, 104 and 156

The SF-36 health survey is a participant-reported survey to measure participant's health. It is a 36-item questionnaire used to measure 8 various aspects of health (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health). The score range for each of the 8 aspects was from 0 (maximum disability) to 100 (no disability), higher scores indicating good health condition. Responses on the SF-36 were also used to calculate 2 summary scores: Physical component score (PCS) and mental component score (MCS). The score range for each of these 2 summary scores was from 0 (maximum disability) to 100 (no disability), where higher score indicated less disability or good health condition. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · units on a scale
Change From Baseline in Mental Component Summary and Physical Component Summary of the Short Form-36 (SF-36) Health Survey at Weeks 26, 52, 104 and 156
units on a scaleGZ/SAR402671
Physical Component Summary: Week 268.39 ± 6.88
Physical Component Summary: Week 527.70 ± 7.76
Physical Component Summary: Week 1049.72 ± 9.02
Physical Component Summary: Week 1565.30 ± 11.83
Mental Component Summary: Week 26-3.31 ± 20.34
Mental Component Summary: Week 521.69 ± 8.27
Mental Component Summary: Week 1046.48 ± 8.14
Mental Component Summary: Week 1562.87 ± 14.17
SecondaryGastrointestinal (GI) Symptoms: Number of Participants With Abdominal Pain at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the presence of abdominal pain in past 10 days (before each of the specified time points). Participants answered the question: "Do you currently suffer from abdominal (tummy) pain? \[Yes/No\]". For this analysis, baseline was defined as initial ACT13739 study.

Time frame:
Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Count of participants · Participants
Gastrointestinal (GI) Symptoms: Number of Participants With Abdominal Pain at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
ParticipantsGZ/SAR402671
Baseline — No5
Baseline — Yes6
Week 2 — No6
Week 2 — Yes5
Week 4 — No7
Week 4 — Yes4
Week 8 — No8
Week 8 — Yes3
Week 12 — No8
Week 12 — Yes2
Week 18 — No7
Week 18 — Yes2
Week 26 — No6
Week 26 — Yes3
Week 52 — No5
Week 52 — Yes2
Week 104 — No5
Week 104 — Yes2
Week 156 — No5
Week 156 — Yes2
SecondaryGastrointestinal Symptoms: Abdominal Pain Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark the severity of the abdominal pain in past 10 days (before each of the specified time points) on a visual analogue scale (VAS). The scale ranged from 0% (no pain) to 100% (very severe), where higher score indicated more severity. For this analysis, baseline was defined as initial ACT13739 study baseline. Standard deviation (SD) can only be calculated when there are more than 1 participant with data available. Thereby, applicable fields were left blank when SD was not calculable.

Time frame:
Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · score on a 0-100 percent scale
Gastrointestinal Symptoms: Abdominal Pain Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
score on a 0-100 percent scaleGZ/SAR402671
Baseline52.50 ± 20.50
Week 235.60 ± 18.47
Week 429.75 ± 20.07
Week 829.00 ± 21.28
Week 1240.00 ± 21.21
Week 1843.00 ± 29.70
Week 2631.33 ± 32.81
Week 5221.00
Week 10421.00
Week 15615.00 ± 7.07
SecondaryGastrointestinal Symptoms: Number of Days With Abdominal Pain Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the number of days they had abdominal pain in past 10 days (before each of the specified time points). Number of days with abdominal pain score was achieved by multiplying number of days with pain \* 10. The score ranges from 10 to 100, where higher score signifies more number of days with pain. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · score on a scale
Gastrointestinal Symptoms: Number of Days With Abdominal Pain Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
score on a scaleGZ/SAR402671
Baseline38.33 ± 31.89
Week 226.00 ± 20.74
Week 425.00 ± 20.82
Week 825.00 ± 23.80
Week 1235.00 ± 7.07
Week 1835.00 ± 21.21
Week 2630.00 ± 34.64
Week 527.00 ± 12.12
Week 1045.00 ± 7.07
Week 15620.00 ± 0.00
SecondaryGastrointestinal Symptoms: Number of Participants With Abdominal Distension at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the presence of abdominal distention in past 10 days (before each of the specified time points). Participants answered the question: "Do you currently suffer from abdominal distension (bloating, swelling or tight tummy)? \[Yes/No\]". For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Count of participants · Participants
Gastrointestinal Symptoms: Number of Participants With Abdominal Distension at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
ParticipantsGZ/SAR402671
Baseline — No9
Baseline — Yes2
Week 2 — No8
Week 2 — Yes3
Week 4 — No7
Week 4 — Yes4
Week 8 — No9
Week 8 — Yes2
Week 12 — No9
Week 12 — Yes1
Week 18 — No8
Week 18 — Yes1
Week 26 — No8
Week 26 — Yes1
Week 52 — No7
Week 52 — Yes0
Week 104 — No7
Week 104 — Yes0
Week 156 — No6
Week 156 — Yes1
SecondaryGastrointestinal Symptoms: Abdominal Distension Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, and 156

Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark the severity of the abdominal distension in past 10 days (before each of the specified time points) on a VAS. The scale ranged from 0% (no distention) to 100% (very severe), where higher score indicated more severity. For this analysis, baseline was defined as initial ACT13739 study baseline. The SD can only be calculated when there are more than 1 participant with data available. Thereby, applicable fields were left blank when SD was not calculable.

Time frame:
Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, and 156 post-ACT13739 baseline
Reported as:
Mean · score on a 0-100 percent scale
Gastrointestinal Symptoms: Abdominal Distension Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, and 156
score on a 0-100 percent scaleGZ/SAR402671
Baseline45.33 ± 24.01
Week 238.67 ± 38.42
Week 421.00 ± 26.15
Week 835.00 ± 48.08
Week 1272.00
Week 1869.00
Week 2680.00
Week 1565.00
SecondaryGastrointestinal Symptoms: Number of Participants in Categories of Response Regarding Eating Less Due to Abdominal Pain/Bloating at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants responded to question "How often do you eat less during meals due to abdominal pain and/or bloating?" in past 10 days (before each of the specified time points) in the categories as 'never', 'occasionally' or 'often'. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Count of participants · Participants
Gastrointestinal Symptoms: Number of Participants in Categories of Response Regarding Eating Less Due to Abdominal Pain/Bloating at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
ParticipantsGZ/SAR402671
Baseline — Never4
Baseline — Occasionally5
Baseline — Often2
Week 2 — Never6
Week 2 — Occasionally3
Week 2 — Often2
Week 4 — Never6
Week 4 — Occasionally3
Week 4 — Often2
Week 8 — Never7
Week 8 — Occasionally3
Week 8 — Often1
Week 12 — Never5
Week 12 — Occasionally3
Week 12 — Often2
Week 18 — Never4
Week 18 — Occasionally3
Week 18 — Often2
Week 26 — Never4
Week 26 — Occasionally3
Week 26 — Often2
Week 52 — Never3
Week 52 — Occasionally3
Week 52 — Often1
Week 104 — Never4
Week 104 — Occasionally3
Week 104 — Often0
Week 156 — Never4
Week 156 — Occasionally3
Week 156 — Often0
SecondaryGastrointestinal Symptoms: Satisfaction Over Bowel Habits at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark their satisfaction over bowel habits in past 10 days (before each of the specified time points) on a VAS. The scale ranged from 0% (very happy) to 100% (very unhappy), where higher percentage indicated less satisfaction. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · score on a 0-100 percent scale
Gastrointestinal Symptoms: Satisfaction Over Bowel Habits at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
score on a 0-100 percent scaleGZ/SAR402671
Baseline26.55 ± 19.09
Week 230.82 ± 21.17
Week 436.09 ± 28.68
Week 834.27 ± 27.02
Week 1221.50 ± 17.83
Week 1823.89 ± 21.29
Week 2635.56 ± 29.37
Week 5219.00 ± 17.05
Week 10418.00 ± 15.18
Week 15634.02 ± 36.67
SecondaryGastrointestinal Symptoms: Frequency of Bowel Movements - Most Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the frequency of their bowel movement (per day or per week or per month) in past 10 days (before each of the specified time points) by answering the question "What is the most number of times you move your bowels per day/week/month?". Participants selected their preferred time unit (e.g., per day). Response provided by participants was converted to number of times per day for reporting the results. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · number of bowel movements per day
Gastrointestinal Symptoms: Frequency of Bowel Movements - Most Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
number of bowel movements per dayGZ/SAR402671
Baseline2.36 ± 1.03
Week 22.00 ± 0.63
Week 42.00 ± 1.00
Week 81.74 ± 1.07
Week 122.04 ± 1.08
Week 182.17 ± 1.05
Week 262.16 ± 1.07
Week 522.08 ± 1.00
Week 1041.96 ± 1.05
Week 1561.65 ± 0.61
SecondaryGastrointestinal Symptoms: Frequency of Bowel Movements - Least Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to report the frequency of their bowel movement (per day or per week or per month) in past 10 days (before each of the specified time points). Participants answered the question "What is the least number of times you move your bowels per day/week/month?". Participants selected their preferred time unit (e.g., per day). Response provided by participants was converted to number of times per day for reporting the results. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · number of bowel movements per day
Gastrointestinal Symptoms: Frequency of Bowel Movements - Least Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
number of bowel movements per dayGZ/SAR402671
Baseline0.78 ± 0.56
Week 20.66 ± 0.43
Week 40.65 ± 0.62
Week 80.62 ± 0.64
Week 120.67 ± 0.65
Week 180.73 ± 0.65
Week 260.75 ± 0.40
Week 520.76 ± 0.72
Week 1040.61 ± 0.49
Week 1560.92 ± 0.62
SecondaryGastrointestinal Symptoms: Influence of GI Symptoms of Fabry Disease on Life at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156

Participants assessed their GI symptoms (abdominal pain, abdominal distention, bowel movements) by completing a questionnaire (modified version of the inflammatory bowel severity scoring system). Participants were asked to mark the influence of their GI symptoms of Fabry disease on life in past 10 days (before each of the specified time points) on a VAS. The scale ranged from 0% (no at all) to 100% (completely), where higher percentage indicated more influence of the GI symptoms of the disease on life. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · score on a 0-100 percent scale
Gastrointestinal Symptoms: Influence of GI Symptoms of Fabry Disease on Life at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156
score on a 0-100 percent scaleGZ/SAR402671
Baseline34.36 ± 26.47
Week 226.73 ± 25.22
Week 421.27 ± 19.88
Week 822.09 ± 19.77
Week 1217.50 ± 19.92
Week 1824.89 ± 23.34
Week 2636.44 ± 30.18
Week 5220.33 ± 22.04
Week 10426.50 ± 23.31
Week 15619.82 ± 21.14
SecondaryGastrointestinal Symptoms: Number of Participants With Stool Consistency Assessment by Bristol Stool Scale Scoring at Baseline and Weeks 26, 52, 104, and 156

Participants were asked to rate their stool consistency in past 10 days (before each of the specified time points) on a 7-point Bristol stool scale, according to the following types: 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces. Types 1 and 2 indicate constipation, types 3 and 4 indicate "ideal stools" (easiest to defecate), and 5-7 tending towards diarrhea. Frequency of each stool type was categorized as 'never', occasionally', or 'often'. For this analysis, baseline was defined as the initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Count of participants · Participants
Gastrointestinal Symptoms: Number of Participants With Stool Consistency Assessment by Bristol Stool Scale Scoring at Baseline and Weeks 26, 52, 104, and 156
ParticipantsGZ/SAR402671
Stool Type 1: Baseline — Never11
Stool Type 1: Baseline — Occasionally0
Stool Type 1: Baseline — Often0
Stool Type 1: Week 26 — Never8
Stool Type 1: Week 26 — Occasionally1
Stool Type 1: Week 26 — Often0
Stool Type 1: Week 52 — Never6
Stool Type 1: Week 52 — Occasionally0
Stool Type 1: Week 52 — Often1
Stool Type 1: Week 104 — Never6
Stool Type 1: Week 104 — Occasionally0
Stool Type 1: Week 104 — Often1
Stool Type 1: Week 156 — Never5
Stool Type 1: Week 156 — Occasionally1
Stool Type 1: Week 156 — Often1
Stool Type 2: Baseline — Never6
Stool Type 2: Baseline — Occasionally5
Stool Type 2: Baseline — Often0
Stool Type 2: Week 26 — Never6
Stool Type 2: Week 26 — Occasionally0
Stool Type 2: Week 26 — Often3
Stool Type 2: Week 52 — Never3
Stool Type 2: Week 52 — Occasionally4
Stool Type 2: Week 52 — Often0
Stool Type 2: Week 104 — Never4
Stool Type 2: Week 104 — Occasionally2
Stool Type 2: Week 104 — Often1
Stool Type 2: Week 156 — Never2
Stool Type 2: Week 156 — Occasionally3
Stool Type 2: Week 156 — Often2
Stool Type 3: Baseline — Never1
Stool Type 3: Baseline — Occasionally4
Stool Type 3: Baseline — Often6
Stool Type 3: Week 26 — Never1
Stool Type 3: Week 26 — Occasionally3
Stool Type 3: Week 26 — Often5
Stool Type 3: Week 52 — Never0
Stool Type 3: Week 52 — Occasionally3
Stool Type 3: Week 52 — Often4
Stool Type 3: Week 104 — Never0
Stool Type 3: Week 104 — Occasionally6
Stool Type 3: Week 104 — Often1
Stool Type 3: Week 156 — Never0
Stool Type 3: Week 156 — Occasionally4
Stool Type 3: Week 156 — Often3
Stool Type 4: Baseline — Never1
Stool Type 4: Baseline — Occasionally8
Stool Type 4: Baseline — Often2
Stool Type 4: Week 26 — Never2
Stool Type 4: Week 26 — Occasionally4
Stool Type 4: Week 26 — Often3
Stool Type 4: Week 52 — Never3
Stool Type 4: Week 52 — Occasionally1
Stool Type 4: Week 52 — Often3
Stool Type 4: Week 104 — Never2
Stool Type 4: Week 104 — Occasionally3
Stool Type 4: Week 104 — Often2
Stool Type 4: Week 156 — Never3
Stool Type 4: Week 156 — Occasionally2
Stool Type 4: Week 156 — Often2
Stool type 5: Baseline — Never1
Stool type 5: Baseline — Occasionally9
Stool type 5: Baseline — Often1
Stool type 5: Week 26 — Never4
Stool type 5: Week 26 — Occasionally4
Stool type 5: Week 26 — Often1
Stool type 5: Week 52 — Never5
Stool type 5: Week 52 — Occasionally2
Stool type 5: Week 52 — Often0
Stool type 5: Week 104 — Never4
Stool type 5: Week 104 — Occasionally1
Stool type 5: Week 104 — Often2
Stool type 5: Week 156 — Never3
Stool type 5: Week 156 — Occasionally3
Stool type 5: Week 156 — Often1
Stool Type 6: Baseline — Never5
Stool Type 6: Baseline — Occasionally5
Stool Type 6: Baseline — Often1
Stool Type 6: Week 26 — Never4
Stool Type 6: Week 26 — Occasionally4
Stool Type 6: Week 26 — Often1
Stool Type 6: Week 52 — Never4
Stool Type 6: Week 52 — Occasionally2
Stool Type 6: Week 52 — Often1
Stool Type 6: Week 104 — Never3
Stool Type 6: Week 104 — Occasionally3
Stool Type 6: Week 104 — Often1
Stool Type 6: Week 156 — Never4
Stool Type 6: Week 156 — Occasionally3
Stool Type 6: Week 156 — Often0
Stool Type 7: Baseline — Never5
Stool Type 7: Baseline — Occasionally5
Stool Type 7: Baseline — Often1
Stool Type 7: Week 26 — Never5
Stool Type 7: Week 26 — Occasionally4
Stool Type 7: Week 26 — Often0
Stool Type 7: Week 52 — Never5
Stool Type 7: Week 52 — Occasionally2
Stool Type 7: Week 52 — Often0
Stool Type 7: Week 104 — Never4
Stool Type 7: Week 104 — Occasionally3
Stool Type 7: Week 104 — Often0
Stool Type 7: Week 156 — Never3
Stool Type 7: Week 156 — Occasionally3
Stool Type 7: Week 156 — Often1
SecondaryChange From Baseline in Beck Depression Inventory (BDI) Total Score at Weeks 26, 104, and 156

The BDI-II Scale was a 21-item scoring tool which measures the existence and severity of symptoms of depression. Each of the 21 items on BDI-II tool represent a depressive symptom. Each symptoms were scored on a 4-point scale of 0 to 3 (0=symptom not present); (3=symptom very intense). Scores for each symptom were added up to obtain the total scores for all 21 items, which were interpreted as follows: Scores of 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression and 29-63: severe depression, where higher scores indicated more depression. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 26, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · score on a scale
Change From Baseline in Beck Depression Inventory (BDI) Total Score at Weeks 26, 104, and 156
score on a scaleGZ/SAR402671
Week 26-0.89 ± 8.13
Week 1042.00 ± 3.37
Week 156-3.43 ± 7.09
SecondaryChange From Baseline in Albumin/Creatinine Ratio (ACR) and Protein/Creatinine Ratio (PCR) at Weeks 26, 52, 104, and 156

For each scheduled visit for this assessment, 3 timed overnight urine samples were collected between 4 to 7 days of each other. All urine samples were collected within a 16-day period. ACR and PCR were determined for each collection. The median of the values determined for the 3 collections/visit was used for analysis. Baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · mg/g
Change From Baseline in Albumin/Creatinine Ratio (ACR) and Protein/Creatinine Ratio (PCR) at Weeks 26, 52, 104, and 156
mg/gGZ/SAR402671
ACR: Week 26-26.22 ± 26.75
ACR: Week 521.00 ± 57.23
ACR: Week 10412.21 ± 71.82
ACR: Week 156-1.14 ± 54.80
PCR: Week 26-38.33 ± 24.40
PCR: Week 520.33 ± 62.11
PCR: Week 104-12.88 ± 76.97
PCR: Week 156-34.38 ± 71.40
SecondaryNumber of Participants in Categories of Echocardiogram (ECHO) Results at Baseline and at Weeks 26, 52, 104, and 156

The summary statistics of all continuous echocardiogram variables were calculated for each visit. The overall interpretation of the readings were summarized in 3 categories: normal, abnormal but not clinically significant (NCS), and abnormal but clinically significant (CS) categories. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Count of participants · Participants
Number of Participants in Categories of Echocardiogram (ECHO) Results at Baseline and at Weeks 26, 52, 104, and 156
ParticipantsGZ/SAR402671
Baseline — Normal6
Baseline — Abnormal NCS2
Baseline — Abnormal CS0
Week 26 — Normal6
Week 26 — Abnormal NCS3
Week 26 — Abnormal CS0
Week 52 — Normal5
Week 52 — Abnormal NCS2
Week 52 — Abnormal CS0
Week 104 — Normal4
Week 104 — Abnormal NCS3
Week 104 — Abnormal CS0
Week 156 — Normal5
Week 156 — Abnormal NCS2
Week 156 — Abnormal CS0
SecondaryNumber of Participants in Categories of Brain Magnetic Resonance Imaging (MRI) Results at Baseline and Weeks 26, and 156

All continuous MRI variables were summarized using descriptive statistics for each visit. The overall interpretation of the readings were summarized in 2 categories as: normal, and abnormal. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 26, and 156 post-ACT13739 baseline
Reported as:
Count of participants · Participants
Number of Participants in Categories of Brain Magnetic Resonance Imaging (MRI) Results at Baseline and Weeks 26, and 156
ParticipantsGZ/SAR402671
Baseline — Normal6
Baseline — Abnormal4
Week 26 — Normal7
Week 26 — Abnormal2
Week 156 — Normal4
Week 156 — Abnormal3
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Weeks 26, 52, 104, and 156

Estimated glomerular filtration rate was used to measure level of kidney function and determine the stage of kidney disease. Change from baseline in eGFR was obtained by subtracting baseline value from post-baseline value at Weeks 26, 52, 104 and 156. For this analysis, baseline was defined as initial ACT13739 study baseline.

Time frame:
Baseline of ACT13739 study and Weeks 26, 52, 104, and 156 post-ACT13739 baseline
Reported as:
Mean · mL/min/1.73m^2
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Weeks 26, 52, 104, and 156
mL/min/1.73m^2GZ/SAR402671
Week 26-3.43 ± 8.64
Week 52-5.57 ± 11.07
Week 104-5.71 ± 10.23
Week 156-4.83 ± 17.54
SecondaryChitotriosidase (Chit1) Plasma Concentration Levels at Weeks 52, 104,156 and 160 (End of Treatment Follow-up)

Plasma concentrations of Chit1 over time were determined using mass spectrometry (MS)-based assay. For the analysis, 52 ng/mL was considered as the lower limit of quantification. Although identified in protocol as a secondary endpoint, plasma Chit1 is also an exploratory measure. Only LTS14116 timepoints were analyzed and are presented. Data summarized are the measured values at each time point (not change from baseline). Here, measured value '0.000' denotes no chitotriosidase detected in plasma for the 5 participants at Week 156 reported by laboratory for all evaluable participants.

Time frame:
Weeks 52, 104, 156 and 160 (End of Treatment Follow-up) post-ACT13739 baseline
Reported as:
Mean · ng/mL
Chitotriosidase (Chit1) Plasma Concentration Levels at Weeks 52, 104,156 and 160 (End of Treatment Follow-up)
ng/mLGZ/SAR402671
Week 5235.965 ± 46.520
Week 10412.785 ± 20.993
Week 1560.000 ± 0.000
Week 160 (End of Treatment Follow-up)6.483 ± 6.309

Adverse events

Collected over From baseline of ACT13739 study up to 37 months post-ACT13739 baseline.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GZ/SAR4026710/11 (0%)3/11 (27.3%)9/11 (81.8%)
Most frequent serious events
Most frequent serious events
EventGZ/SAR402671
HaemolysisBlood and lymphatic system disorders1/11
Deafness unilateralEar and labyrinth disorders1/11
VertigoEar and labyrinth disorders1/11
Floppy infantMusculoskeletal and connective tissue disorders1/11
Ischaemic strokeNervous system disorders1/11
Depressed moodPsychiatric disorders1/11
Intentional self-injuryPsychiatric disorders1/11
Most frequent other events
Showing 10 of 101
Most frequent other events
EventGZ/SAR402671
NasopharyngitisInfections and infestations4/11
HeadacheNervous system disorders4/11
TinnitusEar and labyrinth disorders3/11
Upper respiratory tract infectionInfections and infestations3/11
AngiokeratomaSkin and subcutaneous tissue disorders3/11
CardiomyopathyCardiac disorders2/11
Retinal vascular disorderEye disorders2/11
Gastrooesophageal reflux diseaseGastrointestinal disorders2/11
NauseaGastrointestinal disorders2/11
VomitingGastrointestinal disorders2/11

Baseline characteristics

Analysis performed on all participants who were initially enrolled in the ACT13739 study.

Age, Continuous
Age, Continuous(years)GZ/SAR402671
Mean26.5 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)GZ/SAR402671
Female0
Male11
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GZ/SAR402671
Race — Caucasian/White8
Race — Other3
08

Study locations

7 sites
  • Investigational Site Number 840002
    Atlanta, Georgia 30322, United States
  • Investigational Site Number 840003
    Cincinnati, Ohio 45229, United States
  • Investigational Site Number 840001
    Fairfax, Virginia 22030, United States
  • Investigational Site Number 250001
    Garches, 92380, France
  • Investigational Site Number 616001
    Warszawa, 04-730, Poland
  • Investigational Site Number 643002
    Moscow, 125167, Russian Federation
  • Investigational Site Number 826002
    Cambridge, CB2 OQQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Nov 2018, 40 months.

Results were first posted in Dec 2019, 1 year after primary completion.

Of 11 phase 2 interventional studies under Fabry Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 24. This study's 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2015
First posted
Jul 3, 2015
StartActual
Jul 7, 2015
Primary completionActual
Nov 20, 2018
CompletionActual
Nov 20, 2018
Results first posted
Dec 9, 2019
Last update
Mar 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02489344
Responsible party
Sponsor
First posted
Jul 3, 2015
Start date
Jul 7, 2015
Primary completion
Nov 20, 2018
Completion
Nov 20, 2018
Results posted
Dec 9, 2019
Last update
Mar 23, 2021

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venglustat

Start the discussion